Drug Trial Radar · NCT05259722
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
Last checked: Nov 20, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
513
Actual
Start
Jun 15, 2022
Primary completion
Nov 8, 2023
Study completion Dec 5, 2023
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Feb 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 24-week study in adult participants with severe chronic hand eczema (CHE) and with a documented inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable. Eligible participants will be randomised to receive topical administration of delgocitinib cream 20 mg/g, twice-daily, or oral administration of alitretinoin capsules 30 mg (with an option to reduce to 10 mg during trial conduct), once-daily. The participants will visit the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life. The purpose of this trial is to compare the efficacy, health-related quality of life, and safety of delgocitinib cream and alitretinoin capsules.
Conditions
- Chronic Hand Eczema
Interventions
DelgocitinibDrug
Cream for topical application 20 mg/g
ToctinoDrug
1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HECSI Score From Baseline to Week 12Time frame: 12 weeks
Locations
102 sites in 10 countries. Site status is shown where the registry gives one.
LEO Pharma Investigational Site
Graz, Austria
LEO Pharma Investigational Site
Linz, Austria
LEO Pharma Investigational Site
Linz, Austria
LEO Pharma Investigational Site
Calgary, Canada
LEO Pharma Investigational Site
Calgary, Canada
LEO Pharma Investigational Site
Edmonton, Canada
LEO Pharma Investigational Site
Edmonton, Canada
LEO Pharma Investigational Site
Guelph, Canada
LEO Pharma Investigational Site
London, Canada
LEO Pharma investigational site
London, Canada
LEO Pharma investigational site
Markham, Canada
LEO Pharma investigational site
Niagara Falls, Canada
LEO Pharma Investigational Site
North York, Canada
LEO Pharma investigational site
Québec, Canada
LEO Pharma Investigational Site
Red Deer, Canada
LEO Pharma investigational site
Sherbrooke, Canada
LEO Pharma Investigational Site
Antony, France
LEO Pharma Investigational Site
Martigues, France
LEO Pharma Investigational Site
Montpellier, France
LEO Pharma Investigational Site
Nice, France
LEO Pharma investigational site
Nice, France
LEO Pharma Investigational Site
Reims, France
LEO Pharma Investigational Site
Toulon, France
LEO Pharma Investigational Site
Augsburg, Germany
LEO Pharma Investigational Site
Berlin, Germany
LEO Pharma Investigational Site
Berlin, Germany
LEO Pharma Investigational Site
Bochum, Germany
LEO Pharma Investigational Site
Bochum, Germany
LEO Pharma Investigational Site
Bonn, Germany
LEO Pharma Investigational Site
Darmstadt, Germany
LEO Pharma Investigational Site
Dresden, Germany
LEO Pharma Investigational Site
Erlangen, Germany
LEO Pharma Investigational Site
Essen, Germany
LEO Pharma Investigational Site
Frankfurt, Germany
LEO Pharma Investigational Site
Friedrichshafen, Germany
LEO Pharma Investigational Site
Gera, Germany
LEO Pharma Investigational Site
Göttingen, Germany
LEO Pharma Investigational Site
Halle, Germany
LEO Pharma Investigational Site
Hamburg, Germany
LEO Pharma Investigational Site
Heidelberg, Germany
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.